In Response to the ADM FDA Safety Communication on March 31, 2021

April 7, 2021

Please access the PDF below to read the response to the FDA safety communication on March 31, 2021, titled Acellular Dermal Matrix (ADM) Products Used in Implant-Based Breast Reconstruction Differ in Complication Rates.


PDF: Letter in Response to the March 31, 2021 ADM FDA Safety Communication

Download the PDF